Alira Health’s Take on the EMA DCT Guidance

Last week the European Medicines Agency (EMA) published their “Recommendation Paper on Decentralised Elements in Clinical Trials”, providing guidance on new virtual methods in clinical trials that are rapidly gaining in popularity. Decentralized clinical trials involve the use of remote or virtual technologies to conduct clinical research and have the potential to increase access to clinical trials for both patients and investigators by reducing cost, increasing convenience, and reaching a more diverse pool of participants.

Publications
Published on:
December 19, 2022
Written by:
Jared Adams, MD, PhD
Above all, the Recommendation Paper advises that the patient perspective should guide decentralized protocol development and the benefit-risk calculation of decentralized elements such that 'the rights, safety, dignity and well-being of the trial participants should be protected and prevail over all other interests.'"
Jared Adams, MD, PhD Senior Vice President, Product Management and Design

Paper Summary – The Patient Perspective is Paramount

The Recommendation Paper provides guidance on the design and conduct of decentralized clinical trials. It covers a range of topics, including the use of electronic informed consent, remote monitoring and data collection, stakeholder responsibilities and risk mitigation strategies. Concerns that must be addressed at the protocol stage include questions of generalizability, validity, and handling of missing data. Utilizing multiple systems and parties adds complexity and requires additional oversight. Overall, the recommendation paper emphasizes the importance of ensuring the quality, integrity, and reliability of decentralized clinical trials and provides guidance on how to achieve these goals through the careful consideration of appropriate technologies and protocols.

Above all, the Recommendation Paper advises that the patient perspective should guide decentralized protocol development and the benefit-risk calculation of decentralized elements such that “the rights, safety, dignity and well-being of the trial participants should be protected and prevail over all other interests.”

Alira Health’s Health Storylines – Putting Patients at the Center

At Alira Health, we offer a single patient driven “product lifecycle research platform” in Health Storylines that follows the product from early phase clinical trials to post-marketing and the patient along the entire patient journey until there is patient impact. As a leader in decentralized clinical trials, Alira Health can help stakeholders carefully evaluate the feasibility and suitability of decentralized approaches for a specific trial, and to ensure that appropriate safeguards are in place to mitigate any potential risks.

Related news

News January 25, 2023
Myasthenia Gravis Foundation of America (MGFA) Re-launches the MGFA Global MG Patient Registry with Partner Alira Health
The registry enables patients diagnosed with MG to securely, safely submit their health and symptom data that will help researchers design and drive new research studies and clinical(...)
Clinical Trials Digital Health Patient Advocacy
Publications January 19, 2023
What’s Next for Diabetes: Patient Engagement, Personalization, and Usable Technology
Alira Health partnered with the ADA to support this conversation and explore the most important topics emerging from patients, physicians, specialists, and patient advocates including(...)
Clinical Trials Diabetes MedTech Patient Engagement
Publications December 19, 2022
Alira Health’s Take on the EMA DCT Guidance
Last week the European Medicines Agency (EMA) published their “Recommendation Paper on Decentralised Elements in Clinical Trials”, providing guidance on new virtual methods in clinical(...)
Clinical Trials Decentralized Clinical Trials European Medicines Agency
Multimedia December 17, 2022
Webinar Replay: Partnering with Patients to Streamline Trial Operations: Protocol to Regulatory Submission in 60 days
Learn how patients and patient advocacy organizations can be directly enabled as powerful partners to facilitate all stages of DCT deployment, from protocol design, recruitment, engagement(...)
Clinical Trials Patient Centric Regulatory
Publications November 22, 2022
External Control Arms: The Way to Go?
The growing implementation of Single Arm Trials (SATs) with External Control Arms (ECAs) has been the subject of heated debate across Europe.
Clinical Trials Regulatory
News November 10, 2022
Alira Health and GDMH together to boost Life Sciences innovation
The companies join forces for collaborative research and co-development of projects in the fields of Digital Health, Real-World Evidence and Market Access.
Clinical Trials Digital Health DTx Market Access Real-World Evidence RWE
Multimedia October 27, 2022
RARECast: Leveraging Technology to Empower Patients and Decentralize Clinical Trials
Technology plays a central role in the future of patient empowerment and decentralized clinical trials. Listen to the podcast to learn more.
Decentralized Clinical Trials MedTech
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.